#iDR25 Pre-Conference Workshops

To kick off the iDR25 conference series, two pre-conference workshops will be held for academic researchers and patient representatives.

To kick off the iDR25 conference series, two exclusive pre-conference workshops will be held on 6th May 2025 at the Royal Netherlands Academy of Arts and Sciences (KNAW). The workshops, separate to the conference itself, are primarily aimed at academics, early career researchers and patient representatives looking to increase the understanding of key topics related to medicines repurposing and gain practical skills to apply to current and future drug repurposing projects.

Note: This is registration for the pre-conference workshops only. If you wish to register for the conference, please follow this link: https://remedi4all.org/2025-international-drug-repurposing-conference/.

Workshop 1: Health Technology Assessment: a key tool to patient access

Tuesday 6th May 2025

12:30-14:30

After regulatory approval by the EMA, Health Technology Assessment (HTA) becomes a pivotal process in determining whether new treatments will be accessible to patients, influencing their affordability, availability, and overall impact on healthcare systems. The HTA dossier encapsulates critical information, including the medical, economic, social, and ethical considerations of using a health technology—such as a repurposed medicine. Prepared by the product developer or sponsor, these dossiers undergo evaluation by HTA agencies, like EUnetHTA 21 in the EU or NICE in the UK, to assess their value and feasibility.

This workshop will equip researchers, patient representatives and product developers with the knowledge and tools to design their repurposing projects to meet HTA standards from the onset. With a focus on early alignment with HTA requirements, evidence planning, and incorporating patient engagement into the HTA process from the beginning, attendees will gain actionable insights to streamline their projects through HTA evaluations, enhancing the likelihood of timely patient access.

This workshop offers a unique opportunity to learn proactive strategies to maximise the success of drug repurposing projects in achieving their ultimate goal—reaching and benefiting patients.

Workshop 2: Navigating the regulatory path for medicinal product repurposing

Tuesday 6th May 2025

15:00-17:00

In this workshop, we will discuss the regulatory path and key milestones for advancing a repurposed/repositioned medicinal product from preclinical development to market authorisation in Europe, tailored for academic researchers and early-career developers navigating such processes for the first time. Whether you are preparing for your first clinical trial application or strategising for market authorisation, this session will provide crucial tools and insights to help build your regulatory strategy including:

• Core elements of a Clinical Trial Application (CTA)

• Obtaining Orphan Drug Designations for rare diseases

• Effective engagement with regulatory authorities (e.g. scientific advice)
• Overview of possible registration pathways to bring promising therapies to patients faster
• Building the Common Technical Document (CTD) for a European Marketing Authorisation Application (MAA)

Cancellation policy: All cancellations must be received in writing to [email protected] 21 calendar days prior to the start of the event (16th April 2025). Eventbrite’s ticketing fee is non-refundable.

For cancellation after this time – or if the delegate fails to attend the event, no refund may be expected. Substitutions are welcome at no extra charge up until 1st May 2025.

The organisers reserve the right to cancel the event at any time without liability. In these circumstances, delegates will be offered an alternative date, a credit note, or a full refund.

Data policy: By submitting the order form for this event, you agree that your personal data may be processed by EATRIS as the REMEDi4ALL Coordinator and Beacon (REMEDi4ALL partner managing registrations through Eventbrite)in accordance with REMEDi4ALL Privacy Policy (https://remedi4all.org/privacy-policy/) for the purpose of provision of this event and any related follow up actions (i.e. follow up communications and event reporting).

iDR25 is co-organised by REMEDi4ALL and Beacon.

REMEDi4ALL (https://remedi4all.org/) is an EU-funded research initiative that is driving forward the repurposing of medicines in Europe.

Beacon (https://www.rarebeacon.org/) is a REMEDi4ALL partners UK-based charity that is building a united rare disease community with patient groups at its heart.